<DOC>
	<DOCNO>NCT00306514</DOCNO>
	<brief_summary>The purpose study evaluate whether vaccination Melan-A VLP vaccine lead specific cellular immune response patient malignant melanoma advance stage disease .</brief_summary>
	<brief_title>Safety Immunogenicity Melan-A VLP Vaccine Advanced Stage Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Able provide write informed consent Able willing complete protocol requirement Age : 18 year old Histologically confirm stage III IV melanoma HLAA*0201 haplotype Expected survival least 6 month ECOG performance status 0 1 At least one 2 previous systemic therapy metastatic melanoma Able undergo compute tomography ( CT ) scan/ magnetic resonance imaging ( MRI ) scan tumor assessment . Lack response progression recent systemic therapy metastatic melanoma . Adequate organ bone marrow function All adverse event ( AEs ) prior anticancer therapy resolve â‰¤ Grade 1 Sexually active male use adequate contraception throughout study period 3 month thereafter . Females child bear potential use adequate contraception throughout study period 3 month thereafter , oral contraception doublebarrier local contraception ( intrauterine device plus condom spermicidal gel plus condom ) , negative serum pregnancy test within 4 week prior first dose vaccine . Pregnant nursing Use investigational drug within 30 day enrollment Known suspect brain metastasis Active malignancy 5 year prior enrollment melanoma , basal cell carcinoma cervical carcinoma situ . Major surgery within 4 week prior enrollment . Current use immunosuppressive drug concomitant medication could potentially interfere study drug . Presence significant cardiovascular , renal , pulmonary , endocrine , infectious , neurological disorder . Serum test positive HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) . Active autoimmune disease severe allergy . Known type 1 allergy . Current diagnosis history relevant severe psychiatric disorder compromise patient 's ability understand patient information , give informed consent , comply trial protocol complete study . Blood donation loss &gt; 400mL within 8 week prior inclusion . Hemoglobin ( Hb ) &lt; 10g/dL Abuse alcohol recreational drug . Previous vaccination MelanA peptide analogue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>metastatic malignant melanoma skin</keyword>
</DOC>